Concerning the molecular subtype, 23 patients (37.7%) were diagnosed with TNBC, 32 patients (52.5%) had ER-positive breast cancer, and 6 patients (9.8%) had HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.